Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of heterogenous pathogenesis; environmental, immunologic, genetic, and epigenetic. Long noncoding RNA (lncRNAs) are recently considered emerging biomarkers for diagnosis of SLE. Intense research has been conducted to unveil the association of different lncRNAs and clinical characteristics of SLE as well as disease activity. Objectives: We aim to evaluate the expression level of lncRNA GAS5 in serum of SLE patients in comparison with healthy controls and assess its correlation with Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) Damage Index (SDI). Methods: 30 adult patients with SLE as well as 20 apparently healthy controls. All patients were subjected to full history taking, thorough clinical examination and laboratory investigations in the form of CBC, kidney and liver function tests, acute phase reactants (hsCRP, ESR) and immunological profile (C3, C4, anti-dsDNA antibodies). SLE disease activity was assessed by SLEDAI-2K and SLE damage was assessed by SDI. The expression levels of GAS5 were measured by quantitative real time PCR. Results: LncRNA GAS5 expression levels were insignificantly upregulated in SLE patients compared to control group (p value > 0.05). Their expression levels were not associated with any of clinical or laboratory characteristics of lupus patients except for patients with ocular involvement in whom they were unexpectedly found to be significantly lower (p value 0.03). Also, GAS5 was not associated with SLEDAI-2K or SDI scores. Conclusion: LncRNA GAS5 may be considered a diagnostic biomarker for SLE diagnosis, but not a reliable biomarker for assessment of SLE activity or damage.